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Intravenous acetaminophen (IVA) has rapid and effective analgesic properties. Recent stud-
ies have shown several benefits of using IVA perioperatively. However, due to its relatively
high cost and limited clinical data concerning its efficacy compared with other agents,
physicians are hesitant to use IVA in the perioperative period. This brief review examines
the utility of this medication in the perioperative period and highlights future areas of clinical
and epidemiological research regarding its use.
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INTRODUCTION
Intravenous acetaminophen (IVA), or paracetamol, was made
available in Europe in 2002, but only approved for use in the United
States in November of 2010. IVA has both rapid and effective anal-
gesic properties and is considered to be safe and well tolerated (1).
Physicians are sometimes hesitant to use IVA in the perioperative
period due to its cost and also the relatively limited amount of
available data and supporting studies regarding its efficacy. This
brief review examines several recent studies of IVA and explores
the utility of this medication in the perioperative period.
MECHANISM OF ACTION
The exact mechanism by which acetaminophen produces analge-
sia has yet to be fully elucidated (2). Suggested mechanisms include
inhibition of the synthesis of cyclooxygenases which are involved
in prostaglandin production. It also may act on serotonin path-
ways that regulate spinal nociception. Following surgery, patients
release inflammatory mediators such as histamine, leukotrienes,
cytokines, and prostaglandins. Afferent neurons release glutamate,
substance P, neurokinins, and other peptides (2). IVA may inhibit
the formation of these inflammatory markers and block pain path-
ways to achieve an analgesic effect and reduce pain in patients
postoperatively.
POSTOPERATIVE PAIN
Postsurgical pain has been reported in over 70% of patients,
with 31% of patients reporting severe pain and 47% experienc-
ing moderate levels (2, 3). Additionally, inadequate pain con-
trol contributes to several complications after surgery including
a higher incidence of myocardial infarction, impaired wound
healing, and poor respiratory effort possibly contributing to post-
operative pneumonia (3). However, alleviating pain with current
analgesics such as opiates is not without adverse effects. Opioids
may cause drowsiness, postoperative nausea and vomiting, ileus,
respiratory depression, and bladder dysfunction (4). The addition
of IVA was shown in several studies to decrease the amount of
opiates consumed after surgery, but the reduction of adverse effects
associated with opioids has mixed results (2, 4, 5).
INTRAVENOUS VERSUS ORAL ACETAMINOPHEN
Comparatively, the cost of IVA with oral acetaminophen is several
folds higher, which inhibits many physicians from using the intra-
venous agent. Also, insurance companies reimburse for a fraction
of the cost, resulting in a loss for hospitals. Although cost may be an
issue, there is evidence which favors the intravenous formulation
over the oral agent. The bioavailability of IVA in cerebrospinal fluid
compared with oral acetaminophen after the administration of 1 g
over 6 h is 24.9 versus 14.2µg · h/mL (6). The intravenous route
also produces a higher plasma concentration than oral adminis-
tration and peaks much faster after only 15 min compared with
>45 min with oral acetaminophen (3). Early plasma concentra-
tions of acetaminophen are highly variable when administered
orally and may remain in the subtherapeutic range much longer
than IVA (3). Currently, the correlation of adequate pain con-
trol with cerebrospinal or plasma levels of intravenous and oral
agents has yet to be investigated. Intravenous administration also
produces less of acetaminophen’s toxic metabolite (N -acetyl-p-
benzoquinoneimine) than when ingested orally, making IVA a
safer alternative. Intravenous infusion produces a peak aceta-
minophen concentration in the liver estimated to be 50% less
than the same oral dose (7). Nonetheless the potential for overdose
still exists with IVA and must be carefully monitored in high-risk
patients, such as children and those with liver disease.
INTRAVENOUS ACETAMINOPHEN AND POSTSURGICAL
ANALGESIA
Studies have evaluated the use of IVA in surgical patients under-
going cesarean sections, hysterectomies, coronary artery bypass
grafting, hip or knee replacements, thyroidectomies, and other
surgeries (8). A study looking at IVA use (1 g every 6 h) showed
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a decrease in morphine consumption by 46% (p= 0.0003) on
postoperative day one after total hip replacement or total knee
replacement and found an increased time to receive rescue mor-
phine (hip replacement, 3.9 h and knee replacement, 2.1 h) com-
pared with placebo (0.8 h) (5). Additionally, a recent review of 14
randomized controlled trials found that patients receiving IVA had
improved analgesia in 12 of the studies examined (8). Other stud-
ies in hysterectomy and laminectomy patients suggest that patients
receiving IVA may have a reduction in postoperative nausea and
vomiting, although this has yet to be formally evaluated (8). Fur-
thermore, preemptive (before surgical incision) versus preventive
(after surgical incision) use of IVA was not shown to have a differ-
ence in pain control, but both groups had a decrease in pain scores
6 h after surgery compared with placebo (p< 0.001) (9).
INTRAVENOUS ACETAMINOPHEN IN THE INTENSIVE CARE
UNIT
The use of IVA in the ICU setting also has been investigated. A
study including patients admitted to the ICU after major abdomi-
nal or pelvic surgery examined the amount of opioids used, time to
extubation, and opioid-related adverse effects in patients receiving
1 g of IVA every 6 h over 24 h (4). Time to extubation was reduced
from an average of 204.5± 112.7 min in the referent group com-
pared with only 64.3± 40.6 min in the IVA group (p< 0.01). In
addition, total opiate consumption was significantly reduced in
the IVA group compared with referents. Other studies based in the
ICU have focused on delirium in cardiac surgery patients. Reports
have estimated that over 50% of patients undergoing major cardiac
surgery experience delirium during admission and postoperative
pain and excessive opioid consumption potentially lead to this
complication (10). Although further research is necessary, the use
of IVA in this patient population may reduce the amount of opiate
consumption and subsequently lead to a reduction in the incidence
of delirium.
CONCLUSION
The use of IVA is approved by the Food and Drug Administration
for the management of mild to moderate pain, the management of
moderate to severe pain with opioid analgesic adjuncts, and fever
reduction in adults and children over the age of two (11). Recent
studies have shown several benefits of using IVA perioperatively,
including a reduction in opiate consumption, improved analge-
sia, and reduced postoperative nausea and vomiting. Studies have
not shown a decrease in the incidence of opioid-related adverse
effects, although this may be due to inadequate sample sizes and
difficulty in recording adverse events. Also, the cost effectiveness of
using IVA has not been extensively evaluated in surgical patients.
It is known that the cost of IVA is much higher than oral aceta-
minophen and many hospitals do not support its use during the
perioperative period for this reason. Studies comparing IVA to oral
acetaminophen are lacking and have not shown a benefit in using
IVA compared with the oral formulation (12). More research is
needed in this area to better assess the utility of IVA and to further
evaluate the potential reduction in opioid adverse effects. Addi-
tionally, future clinical and epidemiologic research should examine
the efficacy of IVA compared with oral acetaminophen to deter-
mine the best modality to control postoperative pain and reduce
complications. Since cost is one of the limiting factors for giving
patients IVA, comparative effectiveness studies comparing IVA to
oral acetaminophen which focus on time to post-anesthesia care
unit discharge in both inpatient and outpatient settings are war-
ranted. IVA has the potential to be a very versatile and worthwhile
addition to achieving adequate postoperative analgesia in patients
undergoing a wide variety of surgical procedures and in numerous
hospital settings.
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